Frailty assessments are a good value for their money in older patients considering CABG, according to a study published in the Canadian Journal of Cardiology, but a limited geriatric consultation workforce could curb that benefit in real-life practice.

Analyzing the hearts of chimpanzees and gorillas offered insight into why human hearts evolved as they did in a recent study out of Harvard, the New York Times reports.

Urine flow rate-guided hydration, as opposed to left ventricular end-diastolic pressure-guided hydration, could prevent more complications in CKD patients who are at a high risk for contrast-induced kidney injury.

STEMI is increasingly prevalent among a growing population of patients in their nineties, according to a study published in the American Journal of Cardiology Oct. 11.

Using sex-specific thresholds for high-sensitivity cardiac troponin I assays identified five times more heart attacks in women in a recent study of patients with suspected ACS, but major disparities persisted when it came to treating MIs.

A drop in income over six years was linked to a higher likelihood of CVD in a recent analysis of the ARIC study, suggesting financial stress might be a predictor of worse heart health in the U.S.

The CDC released updated statistics and a new framework for identifying, diagnosing and treating e-cigarette or vaping-related lung disease Oct. 11, putting a name to the recent phenomenon in the process.

Consumer watchdog group U.S. PIRG is criticizing the FDA for “missing their timeline” to review potentially carcinogenic blood pressure medications like losartan, valsartan and irbesartan, arguing the agency needs to step up its efforts to ensure pharmaceutical companies are distributing safe drugs.

An increase in public reporting of aortic valve surgery outcomes has been tied to a decrease in AVR access for patients with infective endocarditis—the unintended consequence of a push for greater transparency in healthcare.

Medtronic on Oct. 7 announced the launch of its EV ICD pivotal study—a prospective, pre-market trial designed to assess the efficacy of an extravascular system in treating dangerous arrhythmias.